Caris Life Sciences, Inc. reported third-quarter revenue of $275.4 million, up 27% year-over-year, with adjusted EBITDA of $44.4 million and GAAP net income of $15.3 million. Management raised full-year revenue guidance to $1.04 billion to $1.05 billion.
CAI · Caris Life Sciences, Inc. · Documents
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Caris reported nine-month revenue of $755.2 million, up 45.5% from $519.1 million, and net income of $14.1 million versus a $(150.0) million loss. Third-quarter revenue rose 27.0% to $275.4 million, while net income fell to $15.3 million from $24.3 million.
Caris Life Sciences reported results for the quarter ended September 30, 2026: total revenue of $275.4 million, up 27%, and net income of $15.3 million. Full-year 2026 revenue guidance raised to $1.04 to $1.05 billion, growth of 28% to 29%.